STOCKWATCH: Waiting for the biotech bubble to burst
This article was originally published in Scrip
Everybody's wondering, when will the biotech bubble burst? Whilst there have been IPOs cancelled citing "market conditions", news of many more primary and secondary offerings continues to appear in our in boxes. Logic dictates that the bubble will burst eventually and indeed in the last year we've already had two warning pops caused by drug pricing concerns, but the NASDAQ Biotech Index has continued its relentless climb. Even so, fresh evidence is appearing that the bubble is about to die, starting with this latest earnings season
You may also be interested in...
The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.
The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.